Feb 6 (Reuters) - Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million. (Reporting by Prakhar Srivastava in Bengaluru;
Agomab Therapeutics Sees 8% Drop in Nasdaq Debut, Valued at $716 Million
Agomab Therapeutics Nasdaq Debut
Feb 6 (Reuters) - Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million.
Initial Market Reaction
(Reporting by Prakhar Srivastava in Bengaluru; Editing by Shailesh Kuber)


